Funding for this research was provided by:
Maastricht University Medical Center
Text and Data Mining valid from 2019-09-06
Received: 9 April 2019
Accepted: 29 July 2019
First Online: 6 September 2019
Compliance with ethical standards
: Tom van Mulken is Chief Medical Officer of the spin off company MicroSure and shareholder in the company. René van der Hulst is shareholder of MicroSure. Raimondo Cau is Chief Technical Officer and shareholder of MicroSure. The other authors declare that they have no conflict of interest.
: Ethical approval for the pre-clinical study on rats was obtained from the Maastricht University Institutional Review Board for Animal Use in Research (Maastricht, the Netherlands; project reference: DEC 2014-078).